Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Boxerman, JL; Schmainda, KM; Zhang, Z; Barboriak, DP

Published Date

  • November 2015

Published In

Volume / Issue

  • 17 / 11

Start / End Page

  • 1538 - 1539

PubMed ID

  • 26361983

Pubmed Central ID

  • PMC4648309

Electronic International Standard Serial Number (EISSN)

  • 1523-5866

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nov163

Language

  • eng

Conference Location

  • England